首页> 外文期刊>Breast cancer >Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens
【24h】

Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens

机译:非典型导管增生和低估的风险:组织取样方法,多焦点性以及相关的钙化严重影响基于后续手术标本的诊断升级率

获取原文
           

摘要

Background Risk assessment and therapeutic options are challenges when counselling patients with an atypical ductal hyperplasia (ADH) to undergo either open surgery or follow-up only. Methods We retrospectively analyzed a series of ADH lesions and assessed whether the morphological parameters of the biopsy materials indicated whether the patient should undergo surgery. A total of 207 breast biopsies [56 core needle biopsies (CNBs) and 151 vacuum-assisted biopsies (VABs)] histologically diagnosed as ADH were analyzed retrospectively, together with subsequently obtained surgical specimens. All histological slides were re-analyzed with regard to the presence/absence of ADH-associated calcification, other B3 lesions (lesion of uncertain malignant potential), extent of the lesion, and the presence of multifocality. Results The overall underestimation rate for the whole cohort was 39% (57% for CNB, 33% for VAB). In the univariate analysis, the method of biopsy (CNB vs VAB, p ?=?0.002) and presence of multifocality in VAB specimens ( p ?=?0.0176) were significant risk factors for the underestimation of the disease (ductal carcinoma in situ or invasive cancer detected on subsequent open biopsy). In the multivariate logistic regression model, the absence of calcification ( p ?=?0.0252) and the presence of multifocality (unifocal vs multifocal ADH, p ?=?0.0147) in VAB specimens were significant risk factors for underestimation. Conclusions Multifocal ADH without associated calcification diagnosed by CNB tends to have a higher upgrade rate. Because the upgrade rate was 16.5% even in the group with the lowest risk (VAB-diagnosed unifocal ADH with calcification), we could not identify a subgroup that would not require an open biopsy.
机译:背景当咨询患有非典型性导管增生(ADH)的患者仅接受开放手术或仅接受随访时,风险评估和治疗选择面临挑战。方法我们回顾性分析了一系列ADH病变,并评估了活检材料的形态学参数是否表明患者是否应该接受手术。回顾性分析了经组织学诊断为ADH的207例乳腺活检[56例核心穿刺活检(CNB)和151例真空辅助活检(VAB)],以及随后获得的手术标本。对所有组织学切片进行重新分析,包括是否存在ADH相关钙化,其他B3病变(恶性潜能不确定的病变),病变程度和多灶性。结果整个队列的总体低估率为39%(CNB为57%,VAB为33%)。在单变量分析中,活检方法(CNB vs VAB,p = 0.002)和VAB标本中存在多灶性(p = 0.0176)是低估该疾病(原发性导管癌或导管癌)的重要危险因素。在随后的开放式活检中检测到浸润性癌)。在多元逻辑回归模型中,VAB标本中没有钙化(p = 0.0252)和多焦点(单焦点与多焦点ADH,p = 0.0147)是低估的重要危险因素。结论CNB诊断为无相关钙化的多灶性ADH倾向于具有更高的升级率。因为即使在风险最低的组(VAB诊断的单灶性ADH伴钙化)中,升级率也为16.5%,所以我们无法确定不需要进行活检的亚组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号